IL224072A - Azothrocyclic bicarbonate carboxamides as p70s6k kinase sequences - Google Patents
Azothrocyclic bicarbonate carboxamides as p70s6k kinase sequencesInfo
- Publication number
- IL224072A IL224072A IL224072A IL22407212A IL224072A IL 224072 A IL224072 A IL 224072A IL 224072 A IL224072 A IL 224072A IL 22407212 A IL22407212 A IL 22407212A IL 224072 A IL224072 A IL 224072A
- Authority
- IL
- Israel
- Prior art keywords
- inhibitors
- kinase p70s6k
- bicyclic
- carboxamides
- azaheterocyclic carboxamides
- Prior art date
Links
- 108010013238 70-kDa Ribosomal Protein S6 Kinases Proteins 0.000 title 1
- 125000002619 bicyclic group Chemical group 0.000 title 1
- 150000003857 carboxamides Chemical class 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
- C07D239/94—Nitrogen atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
- C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
- C07D239/72—Quinazolines; Hydrogenated quinazolines
- C07D239/74—Quinazolines; Hydrogenated quinazolines with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, attached to ring carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Urology & Nephrology (AREA)
- Dermatology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Ophthalmology & Optometry (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Vascular Medicine (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US36896410P | 2010-07-29 | 2010-07-29 | |
| PCT/EP2011/003272 WO2012013282A1 (en) | 2010-07-29 | 2011-07-01 | Bicyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| IL224072A0 IL224072A0 (en) | 2013-03-05 |
| IL224072A true IL224072A (en) | 2016-02-29 |
Family
ID=44532723
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| IL224072A IL224072A (en) | 2010-07-29 | 2012-12-31 | Azothrocyclic bicarbonate carboxamides as p70s6k kinase sequences |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8710044B2 (enExample) |
| EP (1) | EP2598492B1 (enExample) |
| JP (1) | JP5894157B2 (enExample) |
| KR (1) | KR101852644B1 (enExample) |
| CN (1) | CN103003250B (enExample) |
| AR (1) | AR082414A1 (enExample) |
| AU (1) | AU2011285247B2 (enExample) |
| BR (1) | BR112013002090A2 (enExample) |
| CA (1) | CA2806610C (enExample) |
| CL (1) | CL2013000263A1 (enExample) |
| EA (1) | EA023132B1 (enExample) |
| ES (1) | ES2557383T3 (enExample) |
| IL (1) | IL224072A (enExample) |
| MX (1) | MX2013001054A (enExample) |
| NZ (1) | NZ604379A (enExample) |
| SG (1) | SG187166A1 (enExample) |
| UA (1) | UA110113C2 (enExample) |
| WO (1) | WO2012013282A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8563573B2 (en) | 2007-11-02 | 2013-10-22 | Vertex Pharmaceuticals Incorporated | Azaindole derivatives as CFTR modulators |
| US8802868B2 (en) | 2010-03-25 | 2014-08-12 | Vertex Pharmaceuticals Incorporated | Solid forms of (R)-1(2,2-difluorobenzo[D][1,3]dioxo1-5-yl)-N-(1-(2,3-dihydroxypropyl-6-fluoro-2-(1-hydroxy-2-methylpropan2-yl)-1H-Indol-5-yl)-Cyclopropanecarboxamide |
| RU2569678C2 (ru) | 2010-04-22 | 2015-11-27 | Вертекс Фармасьютикалз Инкорпорейтед | Способ получения циклоалкилкарбоксамидо-индольных соединений |
| US9586938B2 (en) * | 2010-07-29 | 2017-03-07 | Merck Patent Gmbh | Cyclic amine azaheterocyclic carboxamides |
| EA023821B1 (ru) * | 2010-11-24 | 2016-07-29 | Мерк Патент Гмбх | Хиназолинкарбоксамидазетидины, их применение в лечении гиперпролиферативных заболеваний и содержащие их композиции |
| ES2646759T3 (es) | 2011-09-12 | 2017-12-15 | Merck Patent Gmbh | Derivados de aminopirimidina para uso como moduladores de la actividad de la quinasa |
| HRP20171554T1 (hr) | 2011-09-12 | 2017-11-17 | Merck Patent Gmbh | Novi imidazol amini kao modulatori aktivnosti kinaze |
| AR093512A1 (es) | 2012-11-16 | 2015-06-10 | Merck Patent Gmbh | Derivados heterociclicos como moduladores de la actividad de cinasas |
| AR093511A1 (es) | 2012-11-16 | 2015-06-10 | Merck Patent Gmbh | Derivados de imidazol-piperidinilo como moduladores de la actividad de cinasas |
| EA033655B1 (ru) * | 2012-11-29 | 2019-11-13 | Merck Patent Gmbh | Производные азахиназолин карбоксамида |
| MX370448B (es) | 2013-03-11 | 2019-12-13 | Merck Patent Gmbh | Derivados de 6- [4- (1h-imidazol-2-il) piperidin-1-il] pirimidin-4-amina como moduladores de la actividad de cinasa. |
| CN103232401B (zh) * | 2013-04-12 | 2015-11-04 | 浙江工业大学 | 一种4-芳硫基喹唑啉类化合物的合成方法 |
| CN103254141B (zh) * | 2013-04-26 | 2016-02-24 | 浙江工业大学 | 4-[4-(2-二丙氨基乙酰氨基)苯胺基]-6-取代喹唑啉类化合物及制备和应用 |
| NZ725361A (en) | 2014-04-03 | 2022-09-30 | Merck Patent Gmbh | Combinations of cancer therapeutics |
| PL3925607T5 (pl) | 2014-04-15 | 2026-06-01 | Vertex Pharmaceuticals Incorporated | Kompozycje farmaceutyczne do leczenia chorób, w których pośredniczy mukowiscydozowy przezbłonowy regulator przewodnictwa |
| JP7723987B2 (ja) * | 2020-04-21 | 2025-08-15 | ユニバーシティ オブ マサチューセッツ | 加齢性黄斑変性を処置するための方法および組成物 |
| IL302951A (en) | 2020-11-16 | 2023-07-01 | Merck Patent Gmbh | Kinase inhibitor combinations for cancer treatment |
| WO2023039068A1 (en) * | 2021-09-08 | 2023-03-16 | Neubase Therapeutics, Inc. | Compositions and methods for synthesis of peptide nucleic acid intermediates |
| WO2026075985A1 (en) * | 2024-10-01 | 2026-04-09 | Neolaia Inc. | Quinoline- and quinazoline-carboxamide derivatives as cd38 inhibitors |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9613021D0 (en) * | 1996-06-21 | 1996-08-28 | Pharmacia Spa | Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
| AR016817A1 (es) * | 1997-08-14 | 2001-08-01 | Smithkline Beecham Plc | Derivados de fenilurea o feniltiourea, procedimiento para su preparacion, coleccion de compuestos, compuestos intermediarios, composicion farmaceutica,metodo de tratamiento y uso de dichos compuestos para la manufactura de un medicamento |
| AU5261001A (en) * | 2000-04-27 | 2001-11-12 | Imperial Cancer Research Technology Ltd | Condensed heteroaryl derivatives |
| TW200306819A (en) | 2002-01-25 | 2003-12-01 | Vertex Pharma | Indazole compounds useful as protein kinase inhibitors |
| AU2003252314A1 (en) * | 2002-08-09 | 2004-02-25 | Kyorin Pharmaceutical Co., Ltd. | 4-substituted quinazoline-8-carboxyamide derivative and pharmaceutically acceptable addition salt thereof |
| JPWO2004014861A1 (ja) * | 2002-08-09 | 2005-12-02 | 杏林製薬株式会社 | ４−置換キノリン−８−カルボン酸アミド誘導体とその薬理上許容される付加塩 |
| US7547794B2 (en) | 2003-04-03 | 2009-06-16 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| US7189729B2 (en) | 2003-09-30 | 2007-03-13 | Irm Llc | Methods and compositions as protein kinase inhibitors |
| US7816353B2 (en) | 2003-10-24 | 2010-10-19 | Exelixis, Inc. | P70S6 kinase modulators and method of use |
| RU2006121646A (ru) | 2003-11-21 | 2008-01-10 | Новартис АГ (CH) | Производные 1h-имидазохинолина в качестве ингибиторов протеинкиназы |
| BRPI0417498A (pt) | 2003-12-09 | 2007-05-29 | Us Gov Health & Human Serv | método para suprimir uma resposta imune em um indivìduo; método de inibição da proliferação de um célula; método de tratamento de um distúrbio proliferativo em um indivìduo; método para selecionar um agente imunossupressor ou anti-proliferativo; composição farmacêutica e estente vascular |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| JP2008501696A (ja) | 2004-06-04 | 2008-01-24 | アンフォラ ディスカバリー コーポレーション | Ａｔｐ利用酵素阻害活性を示すキノリンおよびイソキノリン系化合物、ならびにその組成物および使用 |
| AU2005322085B2 (en) | 2004-12-28 | 2012-07-19 | Exelixis, Inc. | [1H-pyrazolo[3, 4-d]pyrimidin-4-yl]-piperidine or -piperazine compounds as serine-threonine kinase modulators (p70S6K, Atk1 and Atk2) for the treatment of immunological, inflammatory and proliferative diseases |
| GB0501999D0 (en) | 2005-02-01 | 2005-03-09 | Sentinel Oncology Ltd | Pharmaceutical compounds |
| US8343953B2 (en) | 2005-06-22 | 2013-01-01 | Astex Therapeutics Limited | Pharmaceutical compounds |
| UA99284C2 (ru) | 2007-05-11 | 2012-08-10 | Елі Ліллі Енд Компані | ИНГИБИТОРЫ р70 S6-КИНАЗЫ |
| KR101699991B1 (ko) | 2009-02-11 | 2017-01-26 | 메르크 파텐트 게엠베하 | 신규의 아미노 아자헤테로시클릭 카르복사미드 |
-
2011
- 2011-01-07 UA UAA201302432A patent/UA110113C2/uk unknown
- 2011-07-01 EA EA201300186A patent/EA023132B1/ru not_active IP Right Cessation
- 2011-07-01 SG SG2013004965A patent/SG187166A1/en unknown
- 2011-07-01 EP EP11738160.8A patent/EP2598492B1/en active Active
- 2011-07-01 JP JP2013520993A patent/JP5894157B2/ja not_active Expired - Fee Related
- 2011-07-01 WO PCT/EP2011/003272 patent/WO2012013282A1/en not_active Ceased
- 2011-07-01 AU AU2011285247A patent/AU2011285247B2/en not_active Ceased
- 2011-07-01 MX MX2013001054A patent/MX2013001054A/es active IP Right Grant
- 2011-07-01 BR BR112013002090A patent/BR112013002090A2/pt active Search and Examination
- 2011-07-01 US US13/703,276 patent/US8710044B2/en not_active Expired - Fee Related
- 2011-07-01 CN CN201180037284.6A patent/CN103003250B/zh not_active Expired - Fee Related
- 2011-07-01 CA CA2806610A patent/CA2806610C/en active Active
- 2011-07-01 NZ NZ604379A patent/NZ604379A/en not_active IP Right Cessation
- 2011-07-01 ES ES11738160.8T patent/ES2557383T3/es active Active
- 2011-07-01 KR KR1020137005466A patent/KR101852644B1/ko not_active Expired - Fee Related
- 2011-07-29 AR ARP110102741A patent/AR082414A1/es active IP Right Grant
-
2012
- 2012-12-31 IL IL224072A patent/IL224072A/en active IP Right Grant
-
2013
- 2013-01-28 CL CL2013000263A patent/CL2013000263A1/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| KR101852644B1 (ko) | 2018-04-26 |
| US20130137677A1 (en) | 2013-05-30 |
| EP2598492B1 (en) | 2015-10-28 |
| BR112013002090A2 (pt) | 2016-05-24 |
| WO2012013282A8 (en) | 2012-03-29 |
| JP5894157B2 (ja) | 2016-03-23 |
| EA023132B1 (ru) | 2016-04-29 |
| SG187166A1 (en) | 2013-02-28 |
| CA2806610A1 (en) | 2012-02-02 |
| HK1183302A1 (zh) | 2013-12-20 |
| CA2806610C (en) | 2018-08-28 |
| WO2012013282A1 (en) | 2012-02-02 |
| MX2013001054A (es) | 2013-02-21 |
| AR082414A1 (es) | 2012-12-05 |
| EA201300186A1 (ru) | 2013-12-30 |
| AU2011285247A1 (en) | 2013-03-14 |
| IL224072A0 (en) | 2013-03-05 |
| NZ604379A (en) | 2015-01-30 |
| KR20130096714A (ko) | 2013-08-30 |
| UA110113C2 (xx) | 2015-11-25 |
| US8710044B2 (en) | 2014-04-29 |
| CN103003250B (zh) | 2016-02-17 |
| AU2011285247B2 (en) | 2016-08-04 |
| EP2598492A1 (en) | 2013-06-05 |
| JP2013532668A (ja) | 2013-08-19 |
| ES2557383T3 (es) | 2016-01-25 |
| CL2013000263A1 (es) | 2013-09-06 |
| CN103003250A (zh) | 2013-03-27 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| IL224072A0 (en) | Bycyclic azaheterocyclic carboxamides as inhibitors of the kinase p70s6k | |
| AP3210A (en) | Pyrazolyt quinazoline kinase inhibitors | |
| EP2552208A4 (en) | IMIDAZOLYL-IMIDAZOLES AS KINASE INHIBITORS | |
| EP2552214A4 (en) | PYRAZOLYL-PYRIMIDINES AS KINASE INHIBITORS | |
| EP2552211A4 (en) | INDAZOLYL-PYRIMIDINE AS KINASEHEMMER | |
| LT3604510T (lt) | Faktoriaus xa inhibitorius neutralizuojančios medžiagos ir jų naudojimo būdai | |
| EP2576552A4 (en) | BENZOQUINOLONE INHIBITORS OF VMAT2 | |
| IL222227A0 (en) | Pyrazol - 4 - heterocyclyl-carboxamide compounds and methods of use | |
| ZA201300108B (en) | Solid dispersions containing kinase inhibitors | |
| IL215872A (en) | Indomethacin preparation | |
| GB201003274D0 (en) | Methods of connecting | |
| PL3329775T3 (pl) | Sposoby syntezy związków diarylotiohydantoinowych i diarylohydantoinowych | |
| AP3360A (en) | Pyrazole compounds as CRTH2 antagonists | |
| ZA201208489B (en) | Fused bicyclic kinase inhibitors | |
| GB201009731D0 (en) | Kinase inhibitors | |
| ZA201206456B (en) | Uses of dgati inhibitors | |
| IL225605A0 (en) | Polo-like kinase inhibitors | |
| AP2013006987A0 (en) | Heterocyclic compounds suitable for the treatment of dyslipidemia | |
| ZA201208895B (en) | Bicyclic compound derivatives and their use as acc inhibitors | |
| EP2611806A4 (en) | HETEROCYCLIC COMPOUNDS ENRICHED IN DEUTERIUM AS INHIBITORS OF KINASES | |
| ZA201207397B (en) | Process for the preparation of dexlansoprazole | |
| ZA201300012B (en) | Synthesis and use of kinase inhibitors | |
| ZA201300009B (en) | Oral formulation of kinase inhibitors | |
| GB201020357D0 (en) | Compounds and methods of making the same | |
| IL222948A0 (en) | Novel methods for the prepartion of p2x7r antagonists |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FF | Patent granted | ||
| KB | Patent renewed | ||
| KB | Patent renewed | ||
| KB | Patent renewed |